MedAssets Beats on Both Top and Bottom Lines
MedAssets (NAS: MDAS) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), MedAssets beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share grew. GAAP earnings per share grew significantly.
Gross margins dropped, operating margins increased, net margins grew.
MedAssets chalked up revenue of $170.7 million. The 15 analysts polled by S&P Capital IQ foresaw a top line of $167.8 million on the same basis. GAAP reported sales were 4.7% higher than the prior-year quarter's $163.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $0.30. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.26 per share. Non-GAAP EPS of $0.30 for Q2 were 7.1% higher than the prior-year quarter's $0.28 per share. GAAP EPS of $0.08 for Q2 were 100% higher than the prior-year quarter's $0.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 78.0%, 70 basis points worse than the prior-year quarter. Operating margin was 12.8%, 50 basis points better than the prior-year quarter. Net margin was 3.0%, 160 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $167.1 million. On the bottom line, the average EPS estimate is $0.30.
Next year's average estimate for revenue is $679.0 million. The average EPS estimate is $1.29.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 66 members out of 80 rating the stock outperform, and 14 members rating it underperform. Among 31 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give MedAssets a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $21.42.
Is MedAssets the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MedAssets to My Watchlist.
The article MedAssets Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.